Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: Results of a phase 1 study among healthy subjects

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 1, 2013, Pages 21-27

  Dooley, Kelly E ^a   Sayre, Patrick ^a   Borland, Julie ^b   Purdy, Elizabeth ^a   Chen, Shuguang ^b   Song, Ivy ^b   Peppercorn, Amanda ^b   Everts, Stephanie ^a   Piscitelli, Stephen ^b   Flexner, Charles ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

dolutegravir; HIV; pharmacokinetics; rifabutin; rifampin; tuberculosis; UGT1A1

Indexed keywords

ABACAVIR; DOLUTEGRAVIR; EMTRICITABINE; LAMIVUDINE; RIFABUTIN; RIFAMPICIN; TENOFOVIR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LUNG TUBERCULOSIS; LYMPHOCYTOPENIA; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TACHYCARDIA; VIRUS LOAD;

ADULT; ANTITUBERCULAR AGENTS; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; HUMAN EXPERIMENTATION; HUMANS; MALE; MIDDLE AGED; RIFABUTIN; RIFAMPIN;

EID: 84872084395     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318276cda9     Document Type: Article

References (49)

1. World Health Organization. Tuberculosis. Fact sheet 104. March 2012. Available at: http://www.who.int/mediacentre/factsheets/fs104/en/. Accessed September 11, 2012.
2. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362: 697-706.
3. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482-1491.
4. Blanc F, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-1478.
5. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis. N Engl J Med. 2011;365:1492-1501.
6. Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis. 2008;198:948-961.
7. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40:327-341.
8. Naiker S, Conolly C, Weisner L, et al. Pharmacokinetic evaluation of different rifabutin dosing strategies in African TB patients on lopinavir/-ritonavir-based ART. Paper presented at: Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA. Abstract 650.
9. Song I, Chen S, Lou Y, et al. Pharmacokinetic and pharmacodynamic relationship of S/GSK1349572, a next generation integrase inhibitor in HIV-1 infected patients. Paper presented at: International AIDS Society Conference; July, 19-22, 2009; Cape Town, South Africa. Abstract WEPEB250.
10. Stellbrink H, Reynes J, Lazzarin A, et al. Dolutegravir in combination therapy exhibits rapid and sustained antiviral response in ARV-naïve adults: 96-week results from SPRING-1 (ING112276). Paper presented at Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA. #102LB.
11. van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a doseranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12:111-118.
12. Eron J, Kumar P, Lazzarin A, et al. Dolutegravir (DTG, S/GSK1349572) in subjects with HIV exhibiting raltegravir (RAL) resistance: functional monotherapy results of VIKING cohort II. Paper presented at: 18th Annual Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA. Abstract 151LB.
13. Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis. 2011; 204:1811-1815.
14. Song I, Borland J, Chen S, et al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br J Clin Pharmacol. 2011;72:103-108.
15. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1. 0. Available at: http://rsc. tech-res. com/Document/safetyandpharmacovigilance/Table-for-Grading-Severity-of-Adult- Pediatric-Adverse-Events. pdf. Bethesda, MD: Division of AIDS Regulatory Support Center at the National Institutes of Health. Accessed February 11, 2011.
16. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54:254-258.
17. World Health Organization. Rapid advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents-November 2009 [Electronic Version]. Available at: http://www.who.int/hiv/pub/arv/rapid-advice-art.pdf. Geneva, Switzerland: World Health Organization. Accessed February 11, 2011.
18. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 14, 2011;1-167. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed January 10, 2011.
19. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, 2011 Update (WHO/HTM/TB/2011. 6). Geneva, Switzerland: World Health Organization; 2011.
20. Kwara A, Lartey M, Sagoe KW, et al. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS. 2011;25:388-390.
21. DiGiacinto JL, Chan-Tack KM, Robertson SM, et al. Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin. J Clin Pharmacol. 2008;48:518-523.
22. Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G. T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther. 2009; 14:687-695.
23. Nijland HM, L'homme RF, Rongen GA, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS. 2008;22:931-935.
24. Haas DW, Koletar SL, Laughlin L, et al. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twicedaily atazanavir and ritonavir. J Acquir Immune Defic Syndr. 2009;50: 290-293.
25. Schmitt C, Riek M, Winters K, et al. Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers. Arch Drug Inf. 2009;2:8-16.
26. Decloedt EH, McIlleron H, Smith P, et al. Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. Antimicrob Agents Chemother. 2011;55:3195-3200.
27. L'homme RF, Nijland HM, Gras L, et al. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS. 2009;27:863-865.
28. Underwood MR, Vavro CL, Ptak RG, et al. Activity of the next generation integrase inhibitor S/GSK1349572 and two first generation inhibitors across a Broad Panel of HIV Subtype Isolates in PBMCs and MDMs. Paper presented at: XVIII International AIDS Conference, July 18-23, 2010, Vienna, Austria. Abstract MOPE0032.
29. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53:2852-2856.
30. Eron JJ Jr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, activecontrolled, phase 3 non-inferiority trial. Lancet Infect Dis. 2011;11:907-915.
31. Martinez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore). 1999;78:361-369.
32. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis. 1983;5 (suppl 3):S440-S450.
33. Poole G, Stradling P, Worlledge S. Potentially serious side effects of high-dose twice-weekly rifampicin. Br Med J. 1971;3:343-347.
34. Aquinas M, Allan WG, Horsfall PA, et al. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J. 1972;1:765-771.
35. A controlled clinical trial of daily and intermittent regimens of rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis in Hong Kong. A Hong Kong Tuberculosis Treatment Services/Brompton Hospital/British Medical Research Council investigation. Tubercle. 1974;55:1-27.
36. Sekar V, Lavreys L, Van de Casteele T, et al. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother. 2010;54:4440-4445.
37. Griffith DE, Brown BA, Wallace RJ Jr. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus-negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. Clin Infect Dis. 1996;23:1321-1322.
38. Griffith DE, Brown BA, Girard WM, et al. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis. 1995;21: 594-598.
39. Zhang J, Zhu L, Stonier M, et al. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. J Antimicrob Chemother. 2011;66:2075-2082.
40. Barditch-Crovo P, Trapnell CB, Ette E, et al. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther. 1999;65:428-423.
41. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 1996;335:392-398.
42. Apseloff G, Foulds G, LaBoy-Goral L, et al. Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. J Clin Pharmacol. 1998;38:830-835.
43. Hafner R, Bethel J, Standiford HC, et al. Tolerance and pharmacokinetic interactions of rifabutin and azithromycin. Antimicrob Agents Chemother. 2001;45:1572-1577.
44. Trapnell CB, Jamis-Dow C, Klecker RW, et al. Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole. Antimicrob Agents Chemother. 1997;41:924-926.
45. Schmitt C, Riek M, Winters K, et al. Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers. Arch Drug Inf. 2009;2:8-16.
46. Rolla VC, da Silva Vieira MA, Pereira Pinto D, et al. Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis. Clin Drug Investig. 2006;26:469-479.
47. Acosta EP, Kendall MA, Gerber JG, et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother. 2007;51:3104-3110.
48. Grinszteijn B, De Castro N, Arnold V, et al. A randomised trial to estimate efficacy and safety of 2 doses of raltegravir and efavirenz for treatment of HIV-TB co-infected patients: ANRS 12 180 REFLATE TB trial. Paper presented at: 19th International Conference on AIDS; July 22-27, 2012; Washington, DC. Abstract THLBB01.
49. Stellbrink HJ, Albrecht H, Loning T, et al. Herpes simplex virus type-2 ulcers resistant to acyclovir in an AIDS patient-successful treatment with foscarnet. Klin Wochenschr. 1991;69:274-278.